Login to Your Account



Halozyme's Enhanze Platform Nabs Intrexon Deal for A1AT

By Jennifer Boggs


Wednesday, June 8, 2011
On the heels of its deal to apply its delivery technology to ViroPharma Inc.'s hereditary angioedema (HAE) drug, Halozyme Therapeutics Inc. inked another collaboration, this one with stealth biotech Intrexon Corp. valued at a potential $63 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription